A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants

PHASE3CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

July 10, 2015

Primary Completion Date

March 14, 2017

Study Completion Date

March 14, 2017

Conditions
Parkinson's Disease
Interventions
DRUG

TVP-1012 1mg

TVP-1012 1mg Tablets

Trial Locations (56)

Unknown

Nagoya

Matsuyama

Tōon

Kitakyushu

Ōnojō

Asahikawa

Iwamizawa

Akashi

Kobe

Tsuchiura

Tsukuba

Ichinoseki

Morioka

Takamatsu

Fujisawa

Sagamihara

Yokohama

Gōshi

Sendai

Matsumoto

Nishisonogi

Sonogishukugō

Tenri

Jōetsu

Higashiosaka

Suita

Takatsuki

Toyonaka

Irima

Fuji

Hamamatsu

Izunokuni

Shimono

Yoshinogawa

Bunkyo-ku

Fuchū

Kodaira

Meguro-ku

Nerima-ku

Ōta-ku

Setagaya-ku

Shibuya-ku

Akita

Aomori

Fukuoka

Fukushima

Hiroshima

Kochi

Kyoto

Niigata

Okayama

Osaka

Tokushima

Toyama

Wakayama

Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY